Medpacto presents its phase 1 clinical trial results on Vactosertib, an immunotherapy agent, during the upcoming 2018 American Society of Clinical Oncology next month.
Vactosertib is a drug candidate that selectively inhibits TGF-β, a mechanism that inhibits the therapeutic effect of immunotherapy.
The company has been conducting a monotherapy trial on 29 patients since 2014.
During the trial, Medpacto gave 30 to 340 mg of Vactosertib orally to patients, who had end-stage solid tumors and had no therapeutic effects while using conventional anticancer drugs.
As a result, the company saw no dose-limiting toxicity (DLT) in the maximum dosage group. The drug also showed no significant side effects or adverse reactions.
Medpacto has also carried out studies related to using Vactosertib as a combination therapy with other immunotherapeutic drugs on specific biomarkers.
The company has already proved in nonclinical studies that the treatment improves therapeutic effects when combined with other immunotherapeutic drugs such as Keytruda and Obdivo.
The company expects that the treatment will be able to inhibit cancer stem cells, one of the primary mechanisms that resist existing cytotoxic anticancer drugs.
Vactosertib is currently in clinical trials for phase 1b and 2a clinical trials for pancreatic cancer in Korea. In the U.S., the company is conducting phase 1 and 2 clinical trials for multiple myeloma in bone marrow dysplasia.